Coronavirus Update: Oxford Racing Ahead With 8,000 Vaccinated In Phase III Trial
Plus: Eisai Joins RE-MAP Cap Study
Executive Summary
Partnering with AstraZeneca, the Oxford team has opened up a clear lead in the race to enrol thousands of patients for late-stage safety and efficacy trials – but cannot make guarantees of when results might be ready.
You may also be interested in...
Coronavirus Update: 'Positive News' Imminent From Oxford and AstraZeneca Vaccine
More news from across the sector, including Novartis's non-profit pledge on medicines and Zydus Cadila commencing Phase I vaccine trial.
UK Uses Local Outbreak Data To Target Coronavirus Vaccine Trials
The UK Vaccine Taskforce is helping to troubleshoot for COVID-19 candidates including in clinical trials and manufacturing scale-up.
Coronavirus Update: Moderna Hold Up, Sanofi and Regeneron's Kevzara Fails In Phase III
Delay to Moderna's Phase III plans adds to the biotech's rollercoaster ride, but its CEO insists it is still on track.
Existing Subscriber?
Sign in to continue reading.
Need a specific report? 1000+ reports available
Buy Reports
Need a specific report? 1000+ reports available
Buy Reports